We read with interest the recent article by Rajkumar et al on the health care resource
utilization of high-frequency spinal cord stimulation (HF-SCS) in patients with chronic
refractory low back pain (CRLBP).
1
Although the authors present some intriguing findings, we believe that there are
several limitations to the study that warrant consideration.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe toAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Health care resource utilization of high-frequency spinal cord stimulation for treatment of chronic refractory low back pain.Neuromodulation. 2023; 26: 115-123
- Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications.Pain. 2004; 108: 137-147
Article info
Publication history
Accepted:
January 9,
2023
Received:
January 6,
2023
Footnotes
Conflict of Interest: The authors reported no conflict of interest.
Source(s) of financial support: The authors reported no funding sources.
Identification
Copyright
© 2023 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Health Care Resource Utilization of High-Frequency Spinal Cord Stimulation for Treatment of Chronic Refractory Low Back PainNeuromodulationVol. 26Issue 1
- PreviewChronic refractory low back pain (CRLBP) is a diagnosis characterized by chronic low back pain in patients who are poor candidates for surgery and fail conservative management. High-frequency spinal cord stimulation (HF-SCS) is a new advance in neuromodulation that may be effective in treating these patients. However, the cost burden of this therapy is yet undetermined.
- Full-Text
- Preview
